Figure 2.
Kaplan–Meier curves for OS in (A) BRAFi-naive cohort and (B) vemurafenib monotherapy–PD cohort. BRAFi, BRAF inhibitor; NE, not estimable; OS, overall survival; PD, progressive disease.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.